Seattle-based Outpace Bio, a biotech company with a platform that seeks to improve the safety and efficacy of cell and gene therapies, announced it has raised $30 million in Series A funding. The oversubscribed round was led by Artis Ventures and Lyell Immunopharma. Other participants include Abstract Ventures, Civilization Ventures, Mubadala Capital (the asset management arm of Mubadala Investment Company), Playground Global, Sahsen Ventures and WRF Capital.
In addition to the financing, Outpace said it has entered into a collaboration with Lyell for joint research.
Source: Press release